8 news items
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
ARCT
CSLLY
20 May 24
Jon Edelman, M.D., Senior Vice President, Vaccines Innovation Unit, CSL
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
ARCT
CSLLY
20 May 24
President, Vaccines Innovation Unit, CSL.
"We are thrilled that the results of the ARCT-154 study have been
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
ARCT
15 May 24
for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics
Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress
ARCT
8 May 24
to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024
ARCT
25 Apr 24
has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture
375iuj60ng4xjr0jos1fwvak18em8gd687qe912pcsd7ejk 34slo
ARCT
7 Mar 24
an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture
eyrwqt44u1i020zh9nk2t05y5my53bx6iqimkg
ARCT
26 Feb 24
RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus
tirj8o7jb8bxe5lyhst7upzy3u47djvpcuy2fow0lwbcr7wobyky
ARCT
22 Feb 24
RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus
- Prev
- 1
- Next